Product Description
Mechanisms of Action: TGFR Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | Germany | Hungary | Ireland | Italy | Lithuania | Portugal | Spain | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Stryker
Company Location: KALAMAZOO MI 49002
Company CEO: Kevin A. Lobo
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Tibial Fractures|Other
Phase 3: Pain Unspecified
Phase 2: Femoral Fractures|Femoral Neck Fractures|Cleft Lip|Cleft Palate
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BMP7 | N/A |
Terminated |
Femur Head Necrosis |
2017-05-01 |
|
| 2006-006727-39 | P4 |
Completed |
Unknown |
2015-10-18 |
|
| NCT00551941 | P4 |
Terminated |
Tibial Fractures |
2012-07-09 |
|
| The use of BMP for alveolar reconstruction | P2 |
Terminated |
Cleft Palate|Cleft Lip |
2010-11-01 |